Category Archives: Nano Medicine

Global Nano Therapy Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 8.6% during a forecast period.

Global Nano Therapy Market

Market Dynamics

Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanotherapy is a branch of Nano medicine that includes using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process called as targeting.

This report provides insights into the factors that are driving and restraining the global Nano Therapy market. Nanotherapy is also referred to as targeted therapy, which offers to transport the molecules to the affected cells to treat the disease without affecting other negative effects on the healthy cells. Nanoparticles allow for multiple functional groups to be added to the surface. Each of the functional groups contributes to the effectiveness of this method of therapy and deliver its components in a controlled way once it gets to the target cells/tissue. Nano therapy is considered as recent technology for some diseases, which are implemented with the help of submicron-sized molecular devices or nanoparticles. Nanoparticles can improve the drug accessibility in the body with strength, drag out the medication, and can upsurge the half-life of plasma and boost the drug specificity. These are the factors driving the growth of the Nano therapy market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/54507

As compared to the conventional methods, this method has increased more popularity owing to its high accuracy when it comes to administering therapeutic formulations. The market is thriving, with around 250 Nano-medical products being verified or used for humans. Though, with Nano therapy, the carrier is protected from degradations, which allows it to reach given target cells in the body for a local reaction. Nano therapy is considerably used in the treatment of diseases like cancer, diabetes, and cardiovascular diseases. A recent study by the Journal of Diabetes and Metabolic diseases has stated that the incidence of MS ranged from 30.5 to 31.5% in China and 35.8 to 45.3% in India.

However, an absence of controlling standards in the examination of Nano therapy and high expenditure of treatment are several of the major factors that are restraining the growth of the Nano therapy market during the forecast period.

Global Nano Therapy Market Segment analysis

Based on Type, the Nanomaterial segment is anticipated to grow at a CAGR of 20.8% during the forecast period. The nanomaterial is the materials with at least one exterior dimension in the size range of nearly 1 to 100 nanometers. The nanomaterial is intended for developing novel characteristics and has the potential to improve quality of life. The nanomaterial is generally used in cosmetics, healthcare, electronics, and other areas currently. Unceasing development and innovation in the field are impelling the growth of the global nanomaterials market. The amazing chemical and physical properties of materials at the nanometer scale allow novel applications. For instance, energy conservation and structural strength improvement to antimicrobial properties and self-cleaning surfaces. Nanotechnology is being increasingly efficient by spending mainly on R&D activities which are resulting in the development of current technologies and innovations with reference to the new materials.

Global Nano Therapy Market Regional analysis

North America region dominated the Nano therapy market with US$ XX Mn in 2019. The availability of technology, increasing healthcare spending, and government funding for research and development are some of the factors boosting the growth of the Nano therapy market in the region. Europe is expected to follow the Americas and bring in the second leading market share for Nano therapy throughout the forecast period. Europe is mainly driven by awareness and improvement in the nanotechnology sector.

Recent Developments

In 08 May 2019- Cisplatin cis-(diammine) dichloridoplatinum (II) (CDDP) is the first platinum based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck.

In May 2019- A new study conducted by scientists from the Indian Institute of Technology, Bombay, have designed hybrid nanoparticles to treat cancer. These nanoparticles are made from gold and lipids. These nanoparticles respond to light and can be directed inside the body to release drugs to a targeted area, and are biocompatible, meaning theyre not toxic to a human body.

In September 2019, researchers at Finlands University of Helsinki, in partnership with the bo Akademi University and Chinas Huazhong University of Science and Technology developed an anti-cancer nanomedicine useful for targeted cancer chemotherapy.

The objective of the report is to present a comprehensive analysis of the Global Nano Therapy Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Nano Therapy Market dynamics, structure by analyzing the market segments and project the Global Nano Therapy Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Nano Therapy Market make the report investors guide.Scope of the Global Nano Therapy Market

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/54507

Global Nano Therapy Market, By Type

Nanomaterial and Biological Device Nano Electronic Biosensor Molecular Nanotechnology Implantable Cardioverter-DefibrillatorsGlobal Nano Therapy Market, By Application

Cardiovascular Disease Cancer Therapy Diabetes Treatment Rheumatoid ArthritisGlobal Nano Therapy Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Nano Therapy Market

Selecta Biosciences Inc. Cristal Therapeutics Sirnaomics Inc. Nanobiotix Luna CytImmune Science Inc. NanoBio Corporation Nanospectra Biosciences Inc. Nanoprobes Inc. NanoBioMagnetics.n.nu Smith and Nephew NanoMedia Solutions Inc. Nanosphere Inc. DIM Parvus Therapeutics Tarveda Therapeutics

MAJOR TOC OF THE REPORT

Chapter One: Nano Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nano Therapy Market Competition, by Players

Chapter Four: Global Nano Therapy Market Size by Regions

Chapter Five: North America Nano Therapy Revenue by Countries

Chapter Six: Europe Nano Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Nano Therapy Revenue by Countries

Chapter Eight: South America Nano Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nano Therapy by Countries

Chapter Ten: Global Nano Therapy Market Segment by Type

Chapter Eleven: Global Nano Therapy Market Segment by Application

Chapter Twelve: Global Nano Therapy Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nano Therapy Market Report at: https://www.maximizemarketresearch.com/market-report/global-nano-therapy-market/54507/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more:
Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Publicist360

Reusable respirator masks could be a lifeline for health careworkerstrying toprotect themselveswhiletreatingcoronavirus patients.

Theyprovidethesamelevel ofprotection as disposableN95 respirators,which arein short supply around theworld.Theycan beeasily disinfected between patients and shifts. And theylast for months.

But thenationsemergency supply of medicalequipment never stocked them,despiteyears of research predicting direshortfalls of disposablerespirators during a pandemic andrecommendations to stockpilereusableones.

Thedecision not to buy them for the Strategic National Stockpileis inexplicabletoTomFrieden,who led theU.S.Centers forDiseaseControland Preventionuntil 2017.

You can get oneto a health careworker and say,Here's how you clean it and it's yours for theduration of thepandemic, Friedentold USA TODAY. And thoseareon themarket."

Hesaid theCDC predicted as many as 4 billion disposablemasks would beneededin anemergency liketheonethecountry faces now.

An official at theDepartment of Health and Human Services, which oversees thestockpile,said not buying thereusablerespirators was a matter of balancing funding and priorities.

The stockpile hasan alternativeto disposable masks,the official said: battery-powered, air-purifyingmasks.Butthe official,who declined to be identified without authorization,declined to say how many of those are in stock.

Thosedevices, which blow air into the users faces, can becomplicated, noisy and costly.Theyrun$500to $800apiecemany timesmore thana reusable respirator,according to astudyby researchers at the U.S. Department of Veterans Affairspublished in 2015.

Reusablerespirators costbetween$25 and $50;the disposable ones are 25to65 centseach.

In addition to disposable masks, that study recommended stockpiling reusablerespiratorsover air-purifying devices because they cost less and are easier touse.

Officials running thenational stockpileshould havebought reusablerespirators,said Lisa Pompeii, a researcherat Baylor Collegeof Medicine.

Pompeiiis theleadauthor of a study published last week that concluded health careworkers could bequickly fittedfor reusablerespirators and trained on how to usethem.

Theneed is moreurgent thanever.Almost 20% of health careproviders surveyed a weekagohadnorespirators.Another 28% said they werealmost out, according totheAssociation for Professionals in Infection Control andEpidemiology.

Its so discouraging,thesituation wefind ourselves in,said Ann MariePettis, theassociations president-elect.Wereout theretrying to help thosewho aretruly on thefront lines to help them besafeand keep their families safe.

But "so much of what wenormally teach is having to bethrown out thewindow becauseof thelack of supplies, shesaid. Theres all theseweird things weretelling peoplethey can do, suchasreusing disposablemasks.

TheJoint Commission, which accredits hospitals nationwide,altereditspolicyon protectiveequipmentTuesday to allowtheuseof homemademasksan extrememeasureto betaken onlywhenstandardequipmentis unavailable.

Thedeath toll from coronavirus topped 9,600 in the United States on Saturday,with thenumber of confirmed cases rising to337,000, according to Johns Hopkins University.Worldwide, thevirus haskilled more than 70,000 peopleand sickenedmorethan 1.2 million.

Reusable respirators vs. disposable face masks

Reusablerespiratorsarewidely used in manufacturing andotherindustriesto prevent users from inhaling harmful particles, such as thosefromasbestos.Millions of Americans havethemin their garages and on their workbenches.

Researchers specializing in respiratory protection have foundreusablerespirators,known as elastomerics,arealsoeffectivein health care settingsbecause theyofferthe same protectionas a disposable N95 respirator mask.

Thelogistics aremorecomplicated with thereusable, but thebenefits arethat wevegot protection, and you dont haveto worry about it running out, Pompeii, theBaylor researcher, said.

Themasksarefitted for size, just likethedisposablemasks,toensurea properseal.Theycan bewiped down with hospital-gradedisinfectant wipes between patientsand fully sanitized between shifts. They havecartridges thattrapparticles in theair, includingnano-sized ones, saidStella Hines,a professor and researcher at theUniversity of Maryland School of Medicine.

Thevirus at somepoint will dieon thefilterwerenotexactly surehow long, but within days, saidHines, whohas co-authoredseveralstudies on theuseofelastomeric respiratory masks in health care.

"And then as long as that filter doesnt get damaged by being wet,you should beableto usethat filter for a prolongedperiod of time, shesaid.Oneguidelinesays filters can bechangedevery threemonths, shesaid.

Hines is familiar with the respiratorsnot just through herresearch, but becauseemployees at theUniversity of Maryland Medical Centerusethem.

At thebeginningoftheirshifts,workers sign out masks in their size. Theycleanthemwith hospital-gradedisinfectant wipes between patients. At theend of their shifts, therespiratorsaresanitized, saidJim Chang, director of safety andenvironmental health at themedical center.

Theyrewashed, basically, hesaid.Theyredisinfected, dried, packaged, brought back up to thepoint of distribution and theyregood to go for thenext go-around.

The medical center used reusable masks during the 2009 H1N1 pandemic, Chang said, and learned a lot about how to makethem work. Now, weveput all thoselessons back in use.

Health care industry hasn't adopted reusable respirators

Butelastomericshavenot been widely adopted in thehealth careindustry.According to somestudies,workers saytheyrenot as comfortableas disposablemasks andpatients find themscary-looking. In somecases, workers found itmoredifficultto communicatewith patients.

Pompeiinoted that manufacturers havemodified therespirators to makeiteasier tospeak when wearing them.The masks aremadein colors likepurplish pink.

But thelack of widespread usemay havehampered their inclusion in theStrategic National Stockpile.

KerriWizner, anepidemiologistwithMDGuidelinesand lead author of a 2016 studyexaminingrespiratory protectivedevices andemergency preparedness, said themakeup of any medical stockpileshould reflect whats in use.

They want to stock thethings peopleareusing in hospitals, sotheyrenotgoing, 'Usethis thing thats great, but nobodysever used it,Wiznersaid.Inanemergency situationlikewerehaving rightnow, youdont havetheluxury of setting up this fancy program.

Shortages of masks, ventilators needed to treat coronavirus patients

Officialsacross thecountryareventing aboutshortagesof disposablemasks, ventilators and otherequipmentand spiraling pricesas theycompeteagainst oneanother to buy them.

Its thewild, wild west of personal protectiveequipment, Jared Moskowitz, Floridasemergency management director,said Thursday.

Thestateplaced ordersfordisposablerespiratorsmorethan a monthago, hesaid,buthasntbeen told whenthey will arrive.He's now pleadingwith3M,oneof themanufacturers,to selldirectlyto thestaterather than through a distributor.

Nobody really understands who has product, wheretheproduct is or who represents who, hesaid. Frustration is not theword I would use, but theword I would use,you cant print.

Butat theUniversity of MarylandMedical Center, they facenosuchshortage of respirators.

Themedical centerstockpiledelastomericrespiratorsbefore the H1N1 pandemic in 2009.They wereused regularly fora number ofyears beforethey wereput back in storagefor anemergency,Changsaid. Heserved on a National Academies of Sciences,Engineering, and Medicinepanelin 2017 studying theuseofelastomeric respirators in health care, includingsurgesituations.

Themedical centerordered morewhen COVID-19started to spread across China.When the virus struck the United States, workers were fitted and they were passed out toemployees,Chang said.

Chang saidleadership is key when making decisions about how to preparefor a pandemic likethis.

It becomes incumbent upon peoplelikemyself, otheremergency managers, other safety officers,to then sell it to theinstitutions leadership team, that hey, this is a real problem, weneed to beprepared, and this is what you need to do to beprepared.

Read the original:
Reusable respirators protect doctors and nurses against coronavirus, they aren't in the national stockpile - MetroWest Daily News

The "Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme, and Protein Therapy" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses innovation insights across biosimilars, gene therapy, microbiome, robotics, ribozyme, and protein therapy. The TOE also provides technological analysis for recent developments in animal protein applications, microbiome, and cell cultures.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Recent Advancements in the Biotech Industry

Key Industry Contacts

For more information about this report visit https://www.researchandmarkets.com/r/2q5ocu

View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005525/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the rest here:
Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme & Protein Therapy - 2019 - ResearchAndMarkets.com - Yahoo Finance

To find out about politics and inequality in prehistoric Europe, the European Research Council awarded researchers of three countries with a grant of nearly 2 million; among the scientists to participate in the research is Christiana Scheib of the University of Tartu.

The five-year research is led by John Robb, a professor of European prehistory in the Department of Archaeology at the University of Cambridge.

Robbs project, entitled ANCESTORS Making Ancestors: The Politics of Death in Prehistoric Europe receives 1.94 million in funding. The project takes different methods, developed in previous scientific projects, and applies them to a major theoretical problem in European prehistory the nature of community and the rise of inequality, the University of Tartu said in a statement.

This project is really exciting, and Ill be working with wonderful colleagues, Dr Christiana Freddi Scheib at the University of Tartu and Dr Mary Anne Tafuri at Sapienza University of Rome, Robb said.

Christiana Lyn Scheib, a senior research fellow of ancient DNA in the Institute of Genomics of the University of Tartu, has nearly 700,000 at her disposal in the project. According to her, the grant helps study inequality in prehistoric Europe, which is necessary to understand how our distant ancestors lived and what kind of society they lived in. It will give us information regarding how the organisation of society has changed over time, she noted.

Prehistory denotes the period between the introduction of agriculture and the first written records, according to the university.

In the course of the project, the researchers analyse the DNA, skeletons and funeral customs of 400 people who lived in prehistoric times. The subjects of the research come from three historical periods covering the Neolithic or the Later Stone Age (60004000 BC) and the periods from the end of the Stone Age to Early Bronze Age (40001800 BC) and from Intermediate Bronze Age to Iron Age (1800600 BC).

The results of the analysis enable us, for the first time, to estimate how inequality influenced prehistoric Europe and what the role of our ancestors was in it, Scheib said. No research studies of this kind have ever been conducted.

So far, five researchers of the University of Tartu have received the grant of the European Research Council. Among them, a professor of nanomedicine, Tambet Teesalu, has been awarded the grant twice.

Cover: Christiana Scheib (Lumiere studio).

See the original post:
University of Tartu researcher to study inequality in prehistoric Europe - Estonian World

Along with this there is another way also through which the drug can work.

Chloroquine is a weak base an alkaloid. So, when it gets into a membrane-bound structures of the cell organelles (which incidentally are also attacked by the virus), the drug interferes with the acidification of the cell organelles.

The study suggests that chloroquine induces inhibition of acidity-dependent viral fusion in various cell organelles.

The cell organelles thus, including endoplasmic reticulum, Golgi bodies etc. could prevent themselves from becoming centres of viral activity inside the cell.

Favourable outcomes

The cautious optimism over the use of the drug in therapeutic use against the virus does have a scientific basis.

Other combinations of drugs have been tried to treat Covid-19 too; as in the case of a French group study published in the International Journal of Antimicrobial Agents on 20 March this year.

The study involves the treatment of 42 patients with Covid-19, who were treated in-house. Of these, 26 were given hydroxy-chloroquine and the remaining were given the usual care.

Of the 26, six were additionally given antibiotic azithromycin.

By the end of the fifth day, all the six were cured of Covid-19.

Then, among those who took hydroxy-chloroquine alone, seven were completely cured.

In the control group for the same period, only two tested negative for the virus.

Earlier in India, doctors from the Sawai Man Singh hospital in Jaipur had reported how they had cured three patients with a cocktail of anti-viral medicines, a combination of 200mg Lopinavir and 50 mg of Ritonavir twice a day besides Oseltamivir along with chloroquine.

Chloroquine in history

Chloroquine is a synthetic drug. Its natural form is quinine, which in turn is the bark of the cinchona plant.

The indigenous shamanic medicine of Peruvians used it for a long time in curing the illness of Peruvians.

When Christendom conquered Peru, the Jesuits learned the bark powder extraction and then took the knowledge to the West.

Later, as colonialism and Christianity spread, so did malaria to the new lands they conquered.

When the local shamanic knowledge of Peru failed to cure malaria, the missionaries demonstrated the power of their medicine and hence the superiority of their God through the white pills of quinine.

Ethno-botanist Mark J Plotkin has a telling scenario in his famous book The Shamans Apprentince .

Here is an extract from the scholastic version that explains how the missionaries used malarial pills for proselytising:

See the original post:
A Short Introduction To Chloroquine: The Anti-Malarial Drug Being Tested As Cure For Covid-19 - Swarajya

VANCOUVER, March 25, 2020 /PRNewswire/ --Precision Nanosystems, Inc. (PNI), a global leader in enabling transformative nanomedicinesannounced today that the companyentered into a license agreement with FUJIFILM Corporationto adopt PNI's NanoAssemblr technology and complete suite of instruments for Fujifilm'sstate-of-the-art manufacturing facility, compatible with GMP regulations of US, Europe and Japan.

As part of this agreement, Fujifilm has the rights to offer contract manufacturing services using PNI's proprietary technology andalso use PNI technology to develop and commercialize its internal therapeutic drug products. PNI and Fujifilm will work together to combine and democratize the scalable manufacturing of gene therapy and small-molecule based nanomedicines using Fujifilm's and PNI's proprietary technologies.

PNI's NanoAssemblr technology is powered by the disruptive NxGen microfluidics mixing technology designed exclusively for scalable nanomedicine development while maintaining precise control and reproducibility. The NanoAssemblr platform is comprised of the Spark, Ignite, Blaze and GMP Systems that together offer a flexible solution for accelerated, cost-effective development and scalable manufacture of high-quality gene therapy, small molecule and protein-based nanomedicine products.

James Taylor, Co-Founder and CEO of PNI said, "We are thrilled to work with Fujifilm to enable our technology in support of clinical clients as they progress their therapeutic programs from the laboratory to the clinic and commercial. Fujifilm's R&D teams will combinethe PNI platform andtheir proprietary Drug Delivery Systems technologies and we look forward to the seamless scaling up and manufacturing of innovative medicines to impact human well-being."

Nanomedicinesis one of the focus areas of Fujifilm, tapping into itsadvanced technologies such as nano-technology, process engineering technology and analysis technology. "We are excited to work with PNI to bring on board the NanoAssemblr suite of products and cutting-edge nanomedicines manufacturing technology," said Junji Okada, Senior Vice President, General Manager of Pharmaceutical products division, FUJIFILM Corporation. "Tapping into Fujifilm's state of the art technology, expertise and thefacility for the provision of pre-clinical and GMP manufacturing services, we are committed to creating innovative and high-value pharmaceutical productsnot only through internal development but also by providing high quality liposomal formulations to our partner companies."

About Precision NanoSystems Inc.

Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit http://www.precisionnanosystems.com.

About Fujifilm CorporationFUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: http://www.fujifilmholdings.com.

Jane Alleva, Global Marketing Manager, Precision NanoSystems, Phone: 1 888 618 0031, ext 140, mobile 1 778 877 5473

SOURCE Precision Nanosystems

Go here to read the rest:
Precision NanoSystems Announces Partnership with Fujifilm for the Development and GMP Manufacturing of Nanoparticle Based Therapeutics - Yahoo Finance